Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.neuropsych.13060129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A bipolar disorder-associated missense variant alters adenylyl cyclase 2 activity and promotes mania-like behavior.
Mol Psychiatry
January 2025
Molecular Neurogenetics, Max Planck Institute of Psychiatry, 80804, Munich, Germany.
The single nucleotide polymorphism rs13166360, causing a substitution of valine (Val) 147 to leucine (Leu) in the adenylyl cyclase 2 (ADCY2), has previously been associated with bipolar disorder (BD). Here we show that the disease-associated ADCY2 missense mutation diminishes the enzyme´s capacity to generate the second messenger 3',5'-cylic adenosine monophosphate (cAMP) by altering its subcellular localization. We established mice specifically carrying the Val to Leu substitution using CRISPR/Cas9-based gene editing.
View Article and Find Full Text PDFThe engagement of autophagy in maniac disease.
CNS Neurosci Ther
December 2023
Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Aims: Mania is a prevalent psychiatric disorder with undefined pathological mechanism. Here, we reviewed current knowledge indicating the potential involvement of autophagy dysregulation in mania and further discussed whether targeting autophagy could be a promising strategy for mania therapy.
Discussions: Accumulating evidence indicated the involvement of autophagy in the pathology of mania.
Positive allosteric adenosine A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice.
Front Pharmacol
April 2023
International Institute for Integrative Sleep Medicine (WPI-IIIS), Tsukuba, Ibaraki, Japan.
Insomnia is associated with psychiatric illnesses such as bipolar disorder or schizophrenia. Treating insomnia improves psychotic symptoms severity, quality of life, and functional outcomes. Patients with psychiatric disorders are often dissatisfied with the available therapeutic options for their insomnia.
View Article and Find Full Text PDFDifferent oxytocin and corticotropin-releasing hormone system changes in bipolar disorder and major depressive disorder patients.
EBioMedicine
October 2022
Department of Neurobiology and Department of Neurology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; NHC and CAMS key laboratory of Medical Neurobiology, MOE Frontier Science Center for Brain Research and Brain-Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, China. Electronic address:
Background: Oxytocin (OXT) and corticotropin-releasing hormone (CRH) are both produced in hypothalamic paraventricular nucleus (PVN). Central CRH may cause depression-like symptoms, while peripheral higher OXT plasma levels were proposed to be a trait marker for bipolar disorder (BD). We aimed to investigate differential OXT and CRH expression in the PVN and their receptors in prefrontal cortex of major depressive disorder (MDD) and BD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!